- Details
- Charles Ryan, MD, is joined by Veda Giri, MD, Patrick Pilié, MD, and Arpit Rao, MD, MBBS, for a roundtable discussion on DNA repair and Poly (ADP-ribose) polymerase (PARP) inhibitor therapy in prostate cancer. To begin, Dr. Giri discusses the need for widespread genetic testing in the clinic today. Following the May 2020 United States Federal Drug Administration (FDA) approvals of PARP inhibitors...
|
- Details
- Panagiotis Vlachostergios, MD, PhD, joins Alicia Morgans, MD, MPH, to discuss germline and somatic genetic testing and the ways in which genomic material can be integrated into clinical practice. Dr. Morgans and Dr. Vlachostergios agree that patients with metastatic disease, among others, should undergo germline genetic testing, and describe how genetic counselors can help patients make sense of g...
|
- Details
- Ken Pienta, MD, discusses the role of prostate-specific membrane antigen (PSMA) in facilitating personalized medicine as an imaging agent and selection tool for assigning patients to targeted therapy. He mentions the myriad of trials on PSMA radio-ligand therapeutics that have validated its effect in patients for metastatic prostate cancer. James Gulley, MD, Ph.D., FACS, gives an overview of genom...
|
- Details
- Charles Ryan, MD, and Veda Giri, MD discuss consensus building for germline genetic testing in prostate cancer, a relevant topic given the recent FDA approval of two PARP inhibitors. Dr. Giri reflects on results from the Philadelphia Prostate Cancer Consensus Conference held in October 2019, which sought to address some of the challenges that have arisen as testing has increased and to develop a f...
|
- Details
- Elena Castro, Wassim Abida, and Karen Knudsen discuss multiple topics regarding the use of PARP inhibitors in prostate cancer treatments. The three debate PARP response data, the functions of PARP inhibitors, the importance of androgen deprivation in the use of PARP inhibitors, and genomic testing in prostate cancer. Biographies: Karen Knudsen, Ph.D., Director, National Cancer Institute (NCI), Sid...
|
- Details
- Dan Petrylak joins Tom Keane to discuss PARP inhibition in castration-resistant prostate cancer. In this lecture, Dr. Petrylak discusses the germline DNA repair mutations involved in prostate cancer. This is a state of the art lecture establishing the rationale for the clinical trials evaluating PARP inhibitors in metastatic castration-resistant prostate cancer. Biographies: Daniel P. Petrylak, MD...
|
- Details
- Oliver Sartor joins Alicia Morgans to highlight the recently published PROfound Trial. A phase III trial of Lynparza (olaparib) in men with metastatic castration-resistant prostate cancer (mCRPC) who have a homologous recombination repair gene mutation and have progressed on prior treatment with new hormonal agent treatments. The PROfound trial was published in the New England Journal of Medicine...
|
- Details
- Alicia Morgans, Associate Professor of Medicine at Northwestern University, shares her thoughts on genetically informed treatment for advanced and metastatic prostate cancer. Germline and somatic testing can have implications for patients in terms of their therapeutics and the main mutations. Morgans discusses the important germline and somatic mutations as well as the current data from clinical t...
|
- Details
- Wassim Abida, MD, describes his work to facilitate both better understanding of the genomic landscape of prostate cancer while simultaneously integrating new genomic information into clinical practice. In a conversation with Alicia Morgans, MD, MPH, Dr. Abida describes how to identify the subsets of patients that serve to benefit from targeted therapies, referencing the use of pembrolizumab for MS...
|
- Details
- Maha Hussain joins Alicia Morgans sharing an overview of the PROfound study design, it's intent, and specifications on how it was designed to arrive at the answer it was seeking. The PROfound Study, a Phase III, Open-Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cance...
|
